title: Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic Acid and intralesional meglumine antimoniate.
abstract: BACKGROUND
  There are several therapies for treating lupoid leishmaniasis. We compared the effectiveness of intralesional meglumine antimoniate (MA) and topical application of trichloroacetic acid (TCA) 50% solution.
  
  
  METHODS
  This study was a randomized clinical trial comprising 60 lupoid leishmaniasis patients. The first group received intralesional MA once a week, and the second group was treated once weekly with TCA 50% topical solution. The results were recorded once after 8 weeks and then 3 months after the termination of treatment.
  
  
  RESULTS
  The total clearance rates after treatment and after the 3-month follow-up were, respectively, 48.1% and 40% in the first group and 44.4% and 36.6% in the second group. There was no significant difference between the two treatment groups (p=.25 and p=.26). In both groups, the most common side effect was scarring.
  
  
  CONCLUSIONS
  Having almost the same efficacies, TCA as a topical approach could be as effective as MA in the lupoid leishmaniasis treatment plan.
authors.affiliation: Cutaneous Leishmaniasis Research Center, and Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Mahnaz
authors.initials: M
authors.lastname: Banihashemi
authors.affiliation: Cutaneous Leishmaniasis Research Center, and Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Mohamad Javad
authors.initials: MJ
authors.lastname: Yazdanpanah
authors.affiliation: Cutaneous Leishmaniasis Research Center, and Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Hossein
authors.initials: H
authors.lastname: Amirsolymani
authors.affiliation: Cutaneous Leishmaniasis Research Center, and Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Yousefzadehh901@mums.ac.ir.
authors.forename: Hadis
authors.initials: H
authors.lastname: Yousefzadeh
mesh_terms: D000293:Adolescent; D000328:Adult; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D006801:Humans; D015552:Injections, Intralesional; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008536:Meglumine / Q000008:administration & dosage* / Q000009:adverse effects; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome; D014238:Trichloroacetic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D055815:Young Adult
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D014238:Trichloroacetic Acid; D008536:Meglumine; D000077485:Meglumine Antimoniate